Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Frown

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Frown. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-000549-73 Sponsor Protocol Number: MRZ 60201-GL-3001 Start Date*: 2008-05-15
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, open-label, international, multicenter trial to investigate the efficacy and safety of NT 201, free of complexing proteins, in the treatment of glabellar frown lines
    Medical condition: Treatment of glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    10.1 10052609 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004416-78 Sponsor Protocol Number: MRZ 60201-0520/1 Start Date*: 2006-08-30
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, multicenter trial with an open-label extension period to investigate the efficacy and safety of NT 201, free of complexing proteins, in ...
    Medical condition: Treatment of glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002713-40 Sponsor Protocol Number: MRZ60201-GL-3002 Start Date*: 2008-11-06
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, multicenter, randomized, rater- and subject-blind, parallel group trial to investigate the non-inferiority of NT 201, free of complexing proteins, in comparison with Clostridium botu...
    Medical condition: Treatment of glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    10.1 10052609 LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005342-36 Sponsor Protocol Number: MRZ 60201-0609/1 Start Date*: 2007-06-11
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, open-label, multicenter, repeat-dose trial to investigate the safety and efficacy of NT 201, free of complexing proteins, in the treatment of glabellar frown lines
    Medical condition: Treatment of glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005568-24 Sponsor Protocol Number: 214-06/06 Start Date*: 2007-03-29
    Sponsor Name:Dermatologikum Hamburg
    Full Title: Prüfung der Wirksamkeit und der Verträglichkeit von Botulinum-Toxin (Xeomin®) in verschiedenen Verdünnungen Evaluation of the Efficacy and Safety of Botulinumtoxin (Xeomin®) in different dilutions
    Medical condition: Moderate to severe glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002321-34 Sponsor Protocol Number: Y-52-52120-189 Start Date*: 2014-12-04
    Sponsor Name:Ipsen Innovation
    Full Title: A phase III, double blind, randomised, placebo controlled study to assess the efficacy and safety of a single treatment of Clostridium botulinum toxin type A to improve the appearance of moderate t...
    Medical condition: Moderate to severe Glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003667-10 Sponsor Protocol Number: M21-500 Start Date*: 2022-07-08
    Sponsor Name:AbbVie
    Full Title: A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines
    Medical condition: Moderate to Severe Glabellar Lines (GL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-003983-30 Sponsor Protocol Number: CPH-303-201400 Start Date*: 2019-05-22
    Sponsor Name:Croma-Pharma GmbH
    Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study.
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019085-82 Sponsor Protocol Number: Y-52-52120-146 Start Date*: 2011-02-24
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE II, DOUBLE BLIND, RANDOMISED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF THREE DOSES OF DYSPORT RU (20 U, 50 U AND 75 U) ADMINISTERED AS A SINGLE TR...
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003481-41 Sponsor Protocol Number: CPH-201-201461 Start Date*: 2020-01-17
    Sponsor Name:Croma-Pharma GmbH
    Full Title: A Double-Blinded Randomized Controlled Study to Compare the Efficacy, Time to Onset, and Duration of Effect of Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
    Medical condition: moderate to severe glabellar frown lines at maximum frown
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001063-12 Sponsor Protocol Number: EVB-003 Start Date*: 2015-04-22
    Sponsor Name:Evolus Inc.
    Full Title: A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-s...
    Medical condition: moderate-to-severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020057-13 Sponsor Protocol Number: 034-002 Start Date*: 2010-06-11
    Sponsor Name:Dermatologikum Hamburg
    Full Title: Proof-of-concept-study to Evaluate the Efficacy and Tolerability of Repeated Versus Single Treatment with Botulinum-Toxin (Vistabel®) Treatment in Combination with a Hyaluronic Acid (Juvederm-Ultra...
    Medical condition: moderate to severe glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002164-16 Sponsor Protocol Number: CPH-301-201030 Start Date*: 2016-04-11
    Sponsor Name:CROMA-PHARMA GmbH
    Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003841-86 Sponsor Protocol Number: Y-52-52120-214 Start Date*: 2015-04-30
    Sponsor Name:Ipsen Innovation
    Full Title: A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabe...
    Medical condition: Moderate to severe Glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004646-42 Sponsor Protocol Number: 05PF1311 Start Date*: 2014-03-17
    Sponsor Name:Q-MED AB
    Full Title: A randomized, evaluator-blinded, comparative study to evaluate the efficacy and safety of different injection volumes of botulinum toxin type A, Azzalure®, in the glabellar lines.
    Medical condition: Glabella frown lines
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005301-21 Sponsor Protocol Number: MT10109L-005 Start Date*: 2019-06-21
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or ...
    Medical condition: Glabellar Lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005958-23 Sponsor Protocol Number: Y-47-52120-128 Start Date*: 2008-03-03
    Sponsor Name:Ipsen Group, SCRAS Institut Henri Beaufour
    Full Title: A Phase II, Randomised, Double-Blind Study to Compare the Safety and Efficacy of One Treatment Cycle of Clostridium Botulinum Type A Toxin (50 Units) When Reconstituted from Either a 125 Unit or a ...
    Medical condition: Moderate to severe vertical glabellar lines.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004384-31 Sponsor Protocol Number: MT10109L-001 Start Date*: 2019-08-07
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines.
    Medical condition: Glabellar Lines
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004113-13 Sponsor Protocol Number: M602011070 Start Date*: 2020-08-17
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the simultaneous treatment of ...
    Medical condition: Moderate to severe upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral canthal lines)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10048042 Wrinkles LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10052609 Glabellar frown lines LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10052611 Crow's feet LLT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10040954 Skin wrinkling PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001860-36 Sponsor Protocol Number: 191622-142 Start Date*: 2014-12-19
    Sponsor Name:Allergan Limited
    Full Title: Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Forehead and Glabellar Facial Rhytides
    Medical condition: Facial Rhytides (Forehead Lines, Glabellar Lines)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10048043 Wrinkling LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:54:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA